ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Every figure this model derived for ALNY, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 58,697,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 3,308,147,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 4,620,172,000 AssetsCurrent 2026-06-30
current liabilities 1,512,513,000 LiabilitiesCurrent 2026-06-30
equity 1,354,118,000 StockholdersEquity 2026-06-30
interest expense 218,707,000 InterestPaidNet 2025-12-31
ocf 524,080,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 3,713,937,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 348,235,000 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up ALNY on one particular measure came for.

RatioValue
cash operating margin24.38
current ratio3.06
current ratio reported3.05
deferred revenue growth-73.38
dilution pct5.51
ev ebit58.08
ev owner earnings248.69
ev sales7.84
fcf margin12.53
growth cv0.46
interest cover2.29
operating margin13.51
owner earnings margin3.15
revenue growth65.19
revenue growth per share56.56
rule of 4078.7
sbc pct revenue9.38

What to be careful about

What this model itself distrusts about ALNY's figures. Written by the derivation as it ran, not added afterwards.